Statement: Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 17/145 (11.72%)   ANAEMIA 0/145 (0.00%)   LEUKOPENIA 2/145 (1.38%)   NEUTROPENIA 1/145 (0.69%)   LEUKOCYTOSIS 1/145 (0.69%)   THROMBOCYTOPENIA 1/145 (0.69%)   FEBRILE NEUTROPENIA 1/145 (0.69%)   THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%)   DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%)   CARDIAC FAILURE 1/145 (0.69%)   ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2:   Total: 11/144 (7.64%)   ANAEMIA 1/144 (0.69%)   LEUKOPENIA 0/144 (0.00%)   NEUTROPENIA 0/144 (0.00%)   LEUKOCYTOSIS 0/144 (0.00%)   THROMBOCYTOPENIA 0/144 (0.00%)   FEBRILE NEUTROPENIA 1/144 (0.69%)   THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)   DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%)   CARDIAC FAILURE 0/144 (0.00%)   ATRIAL FIBRILLATION 0/144 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 22/79 (27.85%)   Anaemia 0/79 (0.00%)   Right ventricular dysfunction 1/79 (1.27%)   Diarrhoea 1/79 (1.27%)   Vomiting 2/79 (2.53%)   Abdominal pain 0/79 (0.00%)   Colonic obstruction 0/79 (0.00%)   Dysphagia 1/79 (1.27%)   Nausea 1/79 (1.27%)   Mucosal inflammation 1/79 (1.27%)   Performance status decreased 1/79 (1.27%)   Sudden death 1/79 (1.27%) Adverse Events 2:   Total: 13/76 (17.11%)   Anaemia 1/76 (1.32%)   Right ventricular dysfunction 0/76 (0.00%)   Diarrhoea 0/76 (0.00%)   Vomiting 2/76 (2.63%)   Abdominal pain 1/76 (1.32%)   Colonic obstruction 1/76 (1.32%)   Dysphagia 0/76 (0.00%)   Nausea 1/76 (1.32%)   Mucosal inflammation 0/76 (0.00%)   Performance status decreased 0/76 (0.00%)   Sudden death 0/76 (0.00%)